Logo image of IS7.DE

INTICA SYSTEMS SE (IS7.DE) Stock Fundamental Analysis

FRA:IS7 - Deutsche Boerse Ag - DE0005874846 - Common Stock - Currency: EUR

2.1  -0.03 (-1.41%)

Fundamental Rating

2

Taking everything into account, IS7 scores 2 out of 10 in our fundamental rating. IS7 was compared to 52 industry peers in the Electronic Equipment, Instruments & Components industry. IS7 has a bad profitability rating. Also its financial health evaluation is rather negative. IS7 has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

In the past year IS7 has reported negative net income.
IS7 had a positive operating cash flow in the past year.
In multiple years IS7 reported negative net income over the last 5 years.
IS7 had a positive operating cash flow in each of the past 5 years.
IS7.DE Yearly Net Income VS EBIT VS OCF VS FCFIS7.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

1.2 Ratios

IS7 has a worse Return On Assets (-5.05%) than 69.23% of its industry peers.
The Return On Equity of IS7 (-18.79%) is worse than 69.23% of its industry peers.
Industry RankSector Rank
ROA -5.05%
ROE -18.79%
ROIC N/A
ROA(3y)-1.02%
ROA(5y)0.02%
ROE(3y)-3.67%
ROE(5y)-0.35%
ROIC(3y)N/A
ROIC(5y)N/A
IS7.DE Yearly ROA, ROE, ROICIS7.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 -10

1.3 Margins

IS7's Operating Margin has declined in the last couple of years.
IS7 has a better Gross Margin (44.03%) than 63.46% of its industry peers.
In the last couple of years the Gross Margin of IS7 has remained more or less at the same level.
IS7 does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.03%
OM growth 3Y-45.56%
OM growth 5Y-27.46%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.66%
GM growth 5Y1.46%
IS7.DE Yearly Profit, Operating, Gross MarginsIS7.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

2

2. Health

2.1 Basic Checks

IS7 does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IS7 has about the same amount of shares outstanding.
Compared to 5 years ago, IS7 has about the same amount of shares outstanding.
The debt/assets ratio for IS7 is higher compared to a year ago.
IS7.DE Yearly Shares OutstandingIS7.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
IS7.DE Yearly Total Debt VS Total AssetsIS7.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of 1.01, we must say that IS7 is in the distress zone and has some risk of bankruptcy.
IS7's Altman-Z score of 1.01 is on the low side compared to the rest of the industry. IS7 is outperformed by 78.85% of its industry peers.
IS7 has a debt to FCF ratio of 13.05. This is a negative value and a sign of low solvency as IS7 would need 13.05 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 13.05, IS7 is in line with its industry, outperforming 46.15% of the companies in the same industry.
IS7 has a Debt/Equity ratio of 0.38. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of IS7 (0.38) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF 13.05
Altman-Z 1.01
ROIC/WACCN/A
WACC6.02%
IS7.DE Yearly LT Debt VS Equity VS FCFIS7.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M 20M

2.3 Liquidity

IS7 has a Current Ratio of 0.90. This is a bad value and indicates that IS7 is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.90, IS7 is not doing good in the industry: 88.46% of the companies in the same industry are doing better.
A Quick Ratio of 0.48 indicates that IS7 may have some problems paying its short term obligations.
IS7 has a worse Quick ratio (0.48) than 86.54% of its industry peers.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.48
IS7.DE Yearly Current Assets VS Current LiabilitesIS7.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

3

3. Growth

3.1 Past

The earnings per share for IS7 have decreased strongly by -125.17% in the last year.
IS7 shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -18.72%.
IS7 shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.44% yearly.
EPS 1Y (TTM)-125.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1050%
Revenue 1Y (TTM)-18.72%
Revenue growth 3Y-9.65%
Revenue growth 5Y1.44%
Sales Q2Q%-14.86%

3.2 Future

The Earnings Per Share is expected to grow by 42.93% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 5.92% on average over the next years.
EPS Next Y54.29%
EPS Next 2Y42.93%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.36%
Revenue Next 2Y5.92%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IS7.DE Yearly Revenue VS EstimatesIS7.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
IS7.DE Yearly EPS VS EstimatesIS7.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.2 -0.2 0.4 -0.4 -0.6

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IS7. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 69.31, IS7 can be considered very expensive at the moment.
61.54% of the companies in the same industry are cheaper than IS7, based on the Price/Forward Earnings ratio.
IS7's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 37.64.
Industry RankSector Rank
PE N/A
Fwd PE 69.31
IS7.DE Price Earnings VS Forward Price EarningsIS7.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, IS7 is valued a bit cheaper than the industry average as 69.23% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, IS7 is valued cheaper than 90.38% of the companies in the same industry.
Industry RankSector Rank
P/FCF 3.96
EV/EBITDA 6.55
IS7.DE Per share dataIS7.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

IS7's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as IS7's earnings are expected to grow with 42.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.93%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for IS7!.
Industry RankSector Rank
Dividend Yield N/A

INTICA SYSTEMS SE

FRA:IS7 (7/25/2025, 7:00:00 PM)

2.1

-0.03 (-1.41%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)05-28 2025-05-28
Earnings (Next)08-08 2025-08-08
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners60.42%
Ins Owner ChangeN/A
Market Cap9.01M
Analysts45.71
Price Target3.88 (84.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.64%
PT rev (3m)-24%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 69.31
P/S 0.13
P/FCF 3.96
P/OCF 1.88
P/B 0.53
P/tB 0.76
EV/EBITDA 6.55
EPS(TTM)-0.76
EYN/A
EPS(NY)0.03
Fwd EY1.44%
FCF(TTM)0.53
FCFY25.25%
OCF(TTM)1.12
OCFY53.25%
SpS15.76
BVpS3.94
TBVpS2.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.05%
ROE -18.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.03%
FCFM 3.36%
ROA(3y)-1.02%
ROA(5y)0.02%
ROE(3y)-3.67%
ROE(5y)-0.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.7%
ROCE(5y)3.73%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-45.56%
OM growth 5Y-27.46%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.66%
GM growth 5Y1.46%
F-Score4
Asset Turnover1.07
Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF 13.05
Debt/EBITDA 1.23
Cap/Depr 38.1%
Cap/Sales 3.73%
Interest Coverage N/A
Cash Conversion 92.8%
Profit Quality N/A
Current Ratio 0.9
Quick Ratio 0.48
Altman-Z 1.01
F-Score4
WACC6.02%
ROIC/WACCN/A
Cap/Depr(3y)103.63%
Cap/Depr(5y)82.04%
Cap/Sales(3y)7.51%
Cap/Sales(5y)5.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-125.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1050%
EPS Next Y54.29%
EPS Next 2Y42.93%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-18.72%
Revenue growth 3Y-9.65%
Revenue growth 5Y1.44%
Sales Q2Q%-14.86%
Revenue Next Year3.36%
Revenue Next 2Y5.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5474.07%
EBIT growth 3Y-50.82%
EBIT growth 5Y-26.41%
EBIT Next Year1216.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y147.89%
FCF growth 3YN/A
FCF growth 5Y-9.62%
OCF growth 1Y1.52%
OCF growth 3Y29.25%
OCF growth 5Y-6.33%